Page 24 - Molecular features of low-grade developmental brain tumours
P. 24
1
22
CHAPTER 1
References
1. van Breemen, M. S., Wilms, E. B. & Vecht, C. J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6, 421-430, doi:10.1016/S1474-4422(07)70103-5 (2007).
2. Wolf, H. K., Roos, D., Blumcke, I., Pietsch, T. & Wiestler, O. D. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol 91, 376-384, doi:10.1007/s004010050439 (1996).
3. Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131, 803-820, doi:10.1007/s00401-016-1545-1 (2016).
4. van den Bent, M. J. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120, 297-304, doi:10.1007/s00401-010-0725-7 (2010).
5. Bruner, J. M., Inouye, L., Fuller, G. N. & Langford, L. A. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 79, 796-803, doi:10.1002/(sici)1097- 0142(19970215)79:4<796::aid-cncr17>3.0.co;2-v (1997).
6. Blumcke, I. et al. Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification. Nat Rev Neurol 12, 732-740, doi:10.1038/nrneurol.2016.173 (2016).
7. Fukuoka, K. et al. Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas. Neuro Oncol, doi:10.1093/neuonc/noaa077 (2020).
8. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118, 469-474, doi:10.1007/s00401-009-0561-9 (2009).
9. Sturm, D., Pfister, S. M. & Jones, D. T. W. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol 35, 2370-2377, doi:10.1200/JCO.2017.73.0242 (2017).
10. Horbinski, C. et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 21, 564-574, doi:10.1111/j.1750-3639.2011.00480.x (2011).
11. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360, 765-773, doi:10.1056/ NEJMoa0808710 (2009).
12. Dougherty, M. J. et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12, 621-630, doi:10.1093/neuonc/noq007 (2010).
13. Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121, 397-405, doi:10.1007/s00401-011-0802-6 (2011).
14. Chappe, C. et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23, 574-583, doi:10.1111/bpa.12048 (2013).
15. Dahiya, S. et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125, 901-910, doi:10.1007/s00401-013-1120-y (2013).
16. Koelsche, C. et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125, 891-900, doi:10.1007/s00401-013-1100-2 (2013).
17. Prabowo, A. S. et al. BRAF V600E mutation is associated with mTOR signaling activation in
glioneuronal tumors. Brain Pathol 24, 52-66, doi:10.1111/bpa.12081 (2014).
18. Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68, 8673-8677, doi:10.1158/0008-5472.CAN-08-2097
(2008).
